UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037187
Receipt number R000041459
Scientific Title Effects of the Combined Exercise and Game-based Cognitive Training on cancer therapy-related cognitive impairment in patients with breast cancer: Mixed-methods study in the United States and Japan.
Date of disclosure of the study information 2019/07/01
Last modified on 2022/09/02 10:15:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of the Combined Exercise and Game-based Cognitive Training on cancer therapy-related cognitive impairment in patients with breast cancer: Mixed-methods study in the United States and Japan.

Acronym

Effects of the Combined Exercise and Game-based Cognitive Training on cancer therapy-related cognitive impairment in patients with breast cancer: Mixed-methods study in the United States and Japan.

Scientific Title

Effects of the Combined Exercise and Game-based Cognitive Training on cancer therapy-related cognitive impairment in patients with breast cancer: Mixed-methods study in the United States and Japan.

Scientific Title:Acronym

Effects of the Combined Exercise and Game-based Cognitive Training on cancer therapy-related cognitive impairment in patients with breast cancer: Mixed-methods study in the United States and Japan.

Region

Japan North America


Condition

Condition

Breast Cancer

Classification by specialty

Breast surgery Nursing

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to evaluate the effects of a Combined Exercise and Game-based Cognitive Training intervention on cancer therapy-related cognitive changes in patients with breast cancer using a mixed-methods study design in the United States and Japan.

Basic objectives2

Others

Basic objectives -Others

This study aims to compare the differences of the effects of the intervention between the two countries.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Cognitive Function: Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-Cog), The Trail Making Test (TMT) Parts A and B; The time of data collection is baseline, 4 weeks and 12 weeks

Key secondary outcomes

Functional Assessment of Cancer Therapy-General version4 (FACT-G)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Device,equipment

Interventions/Control_1

Intervention group: Combined Exercise and Game-based Cognitive Training
Frequency: Participants will be asked to complete the Combined Exercise and Game-based Cognitive Training exercise sessions three times every week. Study participant perform at least 3 training sessions a week.
Duration: four weeks

Interventions/Control_2

Contorol group: normal living

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Female

Key inclusion criteria

(1) women diagnosed with stage I- III breast cancer
(2) >/=20 years old, </=75 years old
(3) within 6 months to 5 years after completion of chemotherapy; current adjuvant anti-estrogen therapy allowed regardless of other therapies received; current anti-HER-2 therapy allowed.
(4) reporting symptoms of cognitive changes
(5)a Mini-Mental State Examination (MMSE) score of =>24
(6) ECOG (Eastern Cooperative Oncology Group) Performance Status is 0 or 1
(7) understood the disease and treatment (8) able to read and speak English or Japanese
(9) permission of recording an interview data
(10) Consent to participate in the study with consent form

Key exclusion criteria

(1) recurrence
(2) Sequelae of treatment for breast cancer (eg: restricted movement of shoulders and arms, pain) and adverse events (eg: feeling tired, peripheral nerve injury)
(3) diagnosis of mental disorders
(4) history of heart disease, respiratory disease
(5) CNS disease, or orthopedic disease
(6) history of brain or CNS radiation
(7) no one to accompany when it is needed to be assited acompany

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Mika
Middle name
Last name Miyashita

Organization

Hiroshima University

Division name

Gerontological and Oncology Nursing, Graduate School of Biomedical and Health Sciences

Zip code

734-8553

Address

1-2-3, Kasumi, Minami-ku, Hiroshima

TEL

082-257-5385

Email

mikamiya@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name Mika
Middle name
Last name Miyashita

Organization

Hiroshima University

Division name

Gerontological and Oncology Nursing, Graduate School of Biomedical and Health Sciences

Zip code

734-8553

Address

1-2-3, Kasumi, Minami-ku, Hiroshima

TEL

082-257-5385

Homepage URL


Email

mikamiya@hiroshima-u.ac.jp


Sponsor or person

Institute

Gerontological and Oncology Nursing, Graduate School of Biomedical and Health Sciences, Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

Ministry of education, culture, sports, science and technology-Japan

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kumamoto University, University of Kansas, Parker Adventist Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee for Clinical Research of Hiroshima University

Address

1-2-3, Kasumi, Minami-ku, Hiroshima

Tel

082-257-1947

Email

iryo-seisaku@office.hiroshima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

広島大学病院(広島市)


Other administrative information

Date of disclosure of the study information

2019 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2019 Year 04 Month 03 Day

Date of IRB

2019 Year 05 Month 23 Day

Anticipated trial start date

2019 Year 07 Month 01 Day

Last follow-up date

2023 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 06 Month 26 Day

Last modified on

2022 Year 09 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041459


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name